Answers are grounded in this paper and cite their sources.
In the past few years, the herbal mixture PC-SPES had become one of the best prospects for an alternative medicine cancer treatment that would be able to stand up to the intense scrutiny of biomedical research. Previously, the failure to perform adequately in well-designed clinical trials negated further research on alternative medicine products such as laetrile and hydrazine sulfate. Now, with the report by Sovak et al. in this issue of the Journal (1), the fatal flaw with PC-SPES is in the more fundamental issue of product integrity. Although legally sold in the United States as a dietary supplement for “prostate health,” PC-SPES was in fact an alternative medicine treatment for prostate cancer (the PC in the name stands for prostate cancer and spes is Latin for hope). After its release in 1996, the product rapidly became known throughout the prostate cancer patient community. Figures are lacking for the exact rate of use of PC-SPES by patients with prostate cancer, but the results of a University of Virginia survey reported in 1999 showed that 13% of the respondents used an herbal medicine (1a). A similar survey in a radiation oncology clinic in Philadelphia found that 22% of survey respondents used an herbal therapy (2). The University of Virginia study also asked radiation oncologists and urologists to estimate the use of a broad range of complementary and alternative medical therapies by their patients. They guessed 4.4%, whereas the actual figure was 37%. This discrepancy is not surprising given the data indicating that approximately 70% of U.S. patients who use complementary and alternative medical interventions do not reveal the use to their conventional health care practitioner (3). Allegations that PC-SPES contained the synthetic estrogen diethylstilbestrol (DES) began appearing on e-mail listservs of prostate cancer patients and in on-line newsletters by the summer of 2001. One patient who was taking PC-SPES and his wife apparently were concerned enough about this possibility to commission their own analysis of samples from two separate lots in June 2001 (4). Simultaneously, evidence was emerging that the herbal mixture was causing abnormalities in clotting times in some patients and severe bleeding episodes in others (5–7). In this setting, the California Department of Health Services decided to test lots of PC-SPES and found contamination with both DES and warfarin (8). This finding has now been independently verified and extended to include indomethacin by Sovak et al. Uncovering the adulteration of PC-SPES with these synthetic drugs initiated a cascade of effects. On February 8, 2002, the California Department of Health Services released a warning on the contamination of PC-SPES (8). Simultaneously, the California-based manufacturer, BotanicLab, voluntarily recalled PC-SPES nationwide. The Food and Drug Administration (FDA) published a medical product safety alert (9). Canada and Ireland also announced recalls of the product. A multicenter clinical trial comparing PC-SPES and DES was stopped (10). On June 5, 2002, the California Department of Health Services announced that several other herbal products sold by the same company were contaminated with indomethacin, DES, or alprazolam, either individually or in combination. BotanicLabs went out of business on June 1, 2002, and PC-SPES is no longer available (11). Lastly, the National Center for Complementary and Alternative Medicine of the National Institutes of Health placed all its funded grants using PC-SPES on hold pending further review (12). Likely because of the successful marketing of PC-SPES, products with similar names (i.e., PC-Calm, PC-Plus, and PC-Care) and herbal compositions are starting to fill the void. None of these products, however, appears to have any report of research in a search of MEDLINE (July 30, 2002). Unlike most herbal medications, the potential anticancer activities of PC-SPES have been extensively researched, resulting in more than 45 MEDLINE-indexed research articles since the product was released in 1996. PC-SPES was reportedly standardized via high-performance liquid chromatography profiling. Each batch was evaluated for the presence of six specific peaks (13). The main peak is baicalin, a flavone found in high concentration in Scutellaria baicalensis, one of the eight herbs reported in the mixture (14,15). Baicalin is orally bioavailable in rats (16) and is metabolized in the body to baicalein, a flavonoid similar to genistein. (17). Baicalein inhibits 12-lipoxygenase and 5α–reductase (17) and also has aromatase inhibitor activity (18). Aqueous and ethanol PC-SPES extracts have been shown to induce apoptosis and to prolong the G1 phase of the cell cycle in a variety of cancer cell lines (13,19–22). When added to the diet of rats that had been subcutaneously inoculated with a rat prostate cancer cell line, PC-SPES decreased the incidence and growth rate of established tumors (22,23). Four uncontrolled, clinical trial, or case series reports on PC-SPES have been published, each indicating an impressive activity in both androgen-dependent and androgen-independent prostate cancer (24–27). Prostate-specific antigen levels dropped by more than 50% in most patients reported in these studies. One study that used the FACT–P (Functional Assessment of Cancer Therapy–Prostate) questionnaire reported an improved quality of life (25). Objective improvements of bone scans and measurable disease on radiographic imaging studies were noted in some patients (25,27). The estrogen-like side effects of breast tenderness, decreased libido and potency, and thromboembolic events were also frequently observed. Herbal research is complicated enough without having to deal with the added problem of potential product adulteration. Inherent problems in studying herbal extracts arise from the variation in the concentration of active ingredients in herbs caused by 1) known and unknown genetic and environmental factors (28–30); 2) inconsistent and inaccurate identification of plant species (31,32); and 3) contamination by molds, mycotoxins (33), or pesticides (34). Problems may also occur when there is insufficient regulatory oversight of the production facility. Although the source of contamination of BotanicLabs herbal products has not been determined, some have speculated that it originated at the manufacturing plant in China (35). Other instances of herbal products from China being adulterated with synthetic drugs have been reported (36,37). Preclinical and clinical trial research of promising herbal interventions should continue. The fundamental questions raised by herbal medicine, such as the synergistic therapeutic activity of various components, need to be answered for the field to progress. We need to know if there are sufficient reasons (scientific, economic, or other) to continue to pursue research of a product as an incompletely characterized and variable mixture rather than follow the more mainstream drug development model of isolating and purifying an active ingredient. Regulatory challenges also exist. Clinical and, perhaps, preclinical investigators should preferentially study products that at least meet the FDA's newly developed botanic guidelines (38). However, this requirement may not be enough to identify erratic changes in production quality. Consequently, investigators should consider regular quality control evaluations by independent laboratories throughout the course of their research. Much remains to be learned about the mechanism of action of PC-SPES as a cancer therapy in humans. Despite some lots having sufficient concentrations of DES to cause one to wonder if it is responsible for some of the activity, there are intriguing hints that there may be other, possibly novel drug activities present. For example, in the study by Small et al. (27), more than one endocrine manipulation had failed for many of the patients included in the study, and yet some of these patients apparently responded to PC-SPES. The trial comparing DES and PC-SPES (10) was designed so that patients would cross over to the opposite arm after progression. It will be interesting to learn whether analysis of these data shows responses in any patients after the crossover. Perhaps the story of the demise of PC-SPES will serve as a lesson to help future researchers uncover such confounding elements earlier in their research. The story also tells how patient interests and concerns can help push research investigations in positive directions. The lesson must be well learned, because the loss of a product that symbolized hope to some should not occur without leading to an ultimate gain for all cancer patients.
No takes yet. Share an insight, caveat, or question.
Jeffrey D. White (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: